Maraviroc: Integration of a new antiretroviral drug class into clinical practice

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 6, 2008, Pages 1187-1190

  Vandekerckhove, Linos ^a   Verhofstede, Chris ^b   Vogelaers, Dirk ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Chemokine receptor; Co receptor blocker; Tropism; V3 loop sequencing

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MARAVIROC; PLACEBO;

ARTICLE; ASSAY; CD4+ T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

CYCLOHEXANES; DOUBLE-BLIND METHOD; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; TRIAZOLES; VIROLOGY;

EID: 44449134137     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn130     Document Type: Article

References (19)

1. Lalezari J, Goodrich J, DeJesus E et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a Phase 2b/ 3 study in the US and Canada. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 104bLB. http://www.retroconference.org/2007/ Abstracts/30635.htm (24 February 2008, date last accessed).
2. Nelson M, Fätkenheuer G, Konourina I et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 104aLB. http://www.retroconference.org/ 2007/Abstracts/30636.htm (24 February 2008, date last accessed).
3. Petropoulos C, Limoli K, Whitcomb J et al. Validation studies defining the performance of Monogram's HIV coreceptor tropism assay, Trofile. In: Abstracts of the Fifth European HIV Drug Resistance Workshop, Cascais, Portugal, 2007. Abstract 57.
4. Lewis M, James I, Braverman M et al. Evaluation of an ultra-deep sequencing method to identify minority sequence variants in the HIV-1 env gene from clinical samples. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 680. http://www.retroconference.org/2007/ Abstracts/28434.htm (24 February 2008, date last accessed).
5. Westby M, Lewis M, Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80: 4909-20.
6. Mayer H, van der Ryst E, Saag M et al. Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a Phase 2b exploratory trial. In: Abstracts of the Sixteenth International AIDS Conference, Toronto, Canada, 2006 Abstract THLB0215.
7. Lewis M, Mori J, Simpson P et al. Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 871. http://www.retroconference.org/2008/Abstracts/ 32636.htm (24 February 2008, date last accessed).
8. Low AJ, Dong W, Chan D et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007; 21: F17-24.
9. Whitcomb JM, Huang W, Fransen S et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51: 566-75.
10. Trouplin V, Salvatori F, Cappello F et al. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001; 75: 251-9.
11. Van Baelen K, Vandenbroucke I, Rondelez E et al. HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays. J Virol Methods 2007; 146: 61-73.
12. Fouchier RA, Groenink M, Kootstra NA et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66 3183-7.
13. Pillai S, Good B, Richman D et al. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003; 19: 145-9.
14. Sing T, Beerenwinkel N, Kaiser R et al. Geno2pheno[coreceptor]: A tool for predicting coreceptor usage from genotype and for monitoring coreceptor-associated sequence alterations. In: Abstracts of the Third European HIV Drug Resistance Workshop, Athens, Greece, 2005. Abstract A96.
15. Resch W, Hoffman N, Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001; 288: 51-62.
16. Jensen MA, Coetzer M, van 't Wout AB et al. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 2006; 80: 4698-704.
17. Sing T, Harrigan R, Beerenwinkel N et al. Immunologic markers improve genotypic prediction of HIV-1 coreceptor usage. In: Abstracts of the Fourth European HIV Drug Resistance Workshop, Monaco, Monte Carlo, 2006. Abstract A30.
18. Tsibris AM, Kuritzkes DR. Chemokine antagonists as therapeutics: Focus on HIV-1. Annu Rev Med 2007; 58: 445-59.
19. Skrabal K, Low AJ, Dong W et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: Degree of correlation between two phenotypic assays and a bioinformatics model. J Clin Microbiol 2007; 45: 279-84.